trending Market Intelligence /marketintelligence/en/news-insights/trending/mkrt86lb6cuggpbc3vw66a2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Medivir starts layoffs to direct resources toward clinical development projects

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Medivir starts layoffs to direct resources toward clinical development projects

Sweden-based Medivir AB is reducing the number of its employees to 17 from 75 to focus internal resources on clinical development projects.

The company said the layoffs are due to redundancies, mainly within research and administration, and will cut the company's cost base by about two-thirds, freeing up significant resources for the development projects.

In addition, Richard Bethell will leave the position of chief scientific officer. He had been chief scientific officer and executive vice president for research and development since Sept. 1, 2015.

The Sweden-based pharmaceutical company is planning to start late-stage studies for Remetinostat to treat cutaneous T cell lymphoma, a rare kind of blood cancer, and MIV-711 to treat osteoarthritis. Its clinical pipeline also includes treatments for tumors and liver cancer.